Important Things Internists Should Know about Sodium-Glucose Co-Transporter 2 Inhibitors

Main Article Content

Christopher Oleynick https://orcid.org/0000-0002-7297-6673
Pouya Motazedian
Graeme Prosperi-Porta

Abstract

ABSTRACT
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a relatively new class of medications available in Canada used in the treatment of type 2 diabetes mellitus (T2DM). There is an abundance of emerging literature that these drugs are not only effective in the treatment of T2DM but also offer robust clinical benefits for renal disease, cardiovascular disease, and congestive heart failure. Despite the clinical benefits, SGLT-2 inhibitors may be underutilized as some physicians are unfamiliar with the medications or are concerned about their side-effect profile. Given the high prevalence of T2DM and the above comorbidities frequently encountered within Internal Medicine, it is important for internists to be familiar with SGLT-2 inhibitors. This is a short article encapsulating important aspects about these medications that we believe internists should know.


RÉSUMÉ
Les inhibiteurs du cotransporteur sodium-glucose de type 2 (SGLT-2) sont une classe relativement nouvelle de médicaments offerts au Canada et utilisés dans le traitement du diabète de type 2 (DT2). Une profusion de nouvelles études montre que ces médicaments sont non seulement efficaces dans le traitement du DT2, mais qu’ils offrent également de solides avantages cliniques pour les maladies rénales, les maladies cardiovasculaires et l’insuffisance cardiaque congestive. Malgré ces avantages cliniques, les inhibiteurs du SGLT-2 sont peut-être sous-utilisés, car certains médecins ne connaissent pas ces médicaments ou s’inquiètent de leur profil d’effets secondaires. Étant donné la forte prévalence du DT2 et les affections comorbides susmentionnées fréquemment rencontrées en médecine interne, il est important que les internistes connaissent bien les inhibiteurs du SGLT-2. Voici un court article qui résume les aspects importants de ces médicaments que les internistes devraient connaître.

Abstract 199 | pdf Downloads 92 HTML Downloads 131

References

1. Pinto L, Rados D, Remonti L, Kramer C, Leitao C, Gross J. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: A systematic review and meta-analysis. Diabetol Metab Syndr. 2015;7(Suppl 1):A58. https://dx.doi.org/10.1186%2F1758-5996-7-S1-A58
2. Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: A meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications. 2015;29(8):1295–303. http://dx.doi.org/10.1016/j.jdiacomp.2015.07.011
3. Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: A systematic review and meta-analysis. BMJ Open. 2019;9(1):1–15. http://dx.doi.org/10.1136/bmjopen-2018-022577
4. Taylor SI, Blau JE, Rother KI, Beitelshees AL. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks. Lancet Diabetes Endocrinol. 2019;7(12):949–58. http://dx.doi.org/10.1016/S2213-8587(19)30154-8
5. Kashihara N, Kidokoro K, Kanda E. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms. Curr Opin Nephrol Hypertens. 2020;29(1):112–18. http://dx.doi.org/10.1097/MNH.0000000000000561
6. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–54. http://dx.doi.org/10.1016/S2213-8587(19)30256-6
7. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9. http://dx.doi.org/10.1016/S0140-6736(18)32590-X
8. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. http://dx.doi.org/10.1056/NEJMoa1911303
9. Yu X, Zhang S, Zhang L. Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis. Int J Endocrinol. 2018;2018:7074868. http://dx.doi.org/10.1155/2018/7074868
10. Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes. 2018;42:S88–013. http://dx.doi.org/10.1016/j.jcjd.2017.10.034
11. Milder DA, Milder TY, Kam PCA. Sodium-glucose co-transporter type-2 inhibitors: Pharmacology and peri-operative considerations. Anaesthesia. 2018;73(8):1008–18. http://dx.doi.org/10.1111/anae.14251
12. U.S. Food and Drug Administration. SGLT2 inhibitor update [Internet]. FDA Drug Safety Communication; 2020. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious